Effect of sST2 in the Assessment of the Disease Condition and Prognosis of Patients with Heart Failure

doi:10.3969/j.issn.1007-9572.2016.27.023

Abstract

Abstract: Soluble human stromelysin-2 （sST2） is an important serum marker for cardiovascular disease.Studies have shown that sST2 plays a certain role in the pathophysiology of heart failure,and it is an index for reflecting myocardial fibrosis and a new biomarker for heart failure.In this review,multiple relevant studies were reviewed,and the analysis showed that there is close correlation between sST2 level and heart failure risk stratification and prognosis.sST2 can independently predict the prognosis of heart failure,and has certain clinical application value.

Key words: Heart failure, Soluble human stromelysin-2, Prognosis

摘要： 可溶性人基质裂解素2（sST2）是近年发现的重要的心血管疾病血清标志物。近年研究发现，sST2在心力衰竭病理生理学方面存在一定作用，是反映心肌纤维化的指标，亦是心力衰竭新的生物标志物。本文回顾了多项相关研究，分析表明sST2表达水平与心力衰竭的危险分层和预后评估有密切关系，sST2能独立预测心力衰竭预后，有一定临床应用价值。

关键词: 心力衰竭, 可溶性人基质裂解素2, 预后

HU Zhen, ZHANG Xin-chao. Effect of sST2 in the Assessment of the Disease Condition and Prognosis of Patients with Heart Failure[J]. Chinese General Practice, 2016, 19(27): 3375-3379.

胡振, 张新超. 可溶性人基质裂解素2在评估心力衰竭病情和预后中的作用[J]. 中国全科医学, 2016, 19(27): 3375-3379.

References

［1］JANUZZI J L,MEBAZAA A.ST2 and prognosis in acutely decompensated heart failure:the International ST2 Consensus Panel［J］.Am J Cardiol,2015,115（7 Suppl）:26B-31. ［2］KO D T,TU J V,MASOUDI F A,et al.Quality of care and outcomes of older patients with heart failure hospitalized in the United States and Canada［J］.Arch Intern Med,2005,165（21）：e2486-2492. ［3］程凯,徐峰,陈玉国.2015年欧洲《急性心力衰竭院前和院内早期处理共识》解读［J］.中华急诊医学杂志，2015,24（7）:697-700. ［4］DANIELS L B,MAISEL A S.Natriuretic peptides［J］.JACC，2007，50（25）：2357-2368. ［5］CHEN A A，WOOD M J，KRAUSER D G，et al.NT-proBNP levels，echocardiographic findings，and outcomes in breathless patients：results from the ProBNP investigation of Dyspnea in the Emergency Department （PRIDE） echocardiographic substudy［J］.Euro Heart J，2006，27（7）：839-845. ［6］JANUZZI J L，JR REHMAN S，MUELLER T，et al.Importance of biomarkers for long term mortality prediction in acutely dyspneic patients［J］.Clin Chem，2010，56（12）：1814-1821. ［7］JANUZZI JL J R,SAKHUJA R,O’DONOGHUE M,et al.Utility of aminoterminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department［J］.Arch Intern Med,2006,166（3）:315-320. ［8］KARAYANNIS G,TRIPOSKIADIS F,SKOULARIGIS J，et al.The emerging role of Galectin-3 and ST2 in heart failure：practical considerations and pitfalls using novel biomarkers［J］.Curr Heart Fail Rep，2013，10（4）：441-449. ［9］MAEDER M T,RICKENBACHER P，RICKI H,et al.N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction:findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure （TIME-CHF）［J］.Eur J Heart Fail,2013,15（10）:1148-1156. ［10］LAINCHBURY J G,TROUGHTON R W,FRAMPTON C M,et al.NTproBNP-guided drug treatment for chronic heart failure:design and methods in the "BATTLESCARRED" trial［J］.Eur J Heart Fail,2006,8（5）:532-538. ［11］EURLINGS L M,VAN POL P E,KOK W E,et al.Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets:results of the PRIMA （Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?） study［J］.J Am Coll Cardiol,2010,56（25）:2090-2100. ［12］WEINBERG E O,SHIMPO M,DE KEULENAER G W,et al.Expression and regulation of ST2,an interleukin-1 receptor family member,in cardiomyocytes and myocardial infarction［J］.Circulation,2002,106（23）:2961-2966. ［13］JANUZZI JL J R,PEACOCK W F,MAISEL A S,et al.Measurement of the interleukin family member ST2 in patients with acute dyspnea:results from the PRIDE （Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department） study［J］.J Am Coll Cardiol,2007,50:607-613. ［14］BOISOT S,BEEDE J,ISAKSON S,et al.Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure［J］.J Card Fail,2008,14（9）:732-738. ［15］KY B,FRENCH B,MCCLOSKEY K,et al.High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure［J］.Circ Heart Fail,2011,4（2）:180-187. ［16］石金铮.ST2和hs-CRP在急性冠脉综合征中的诊断价值及其在急性心肌梗死后左室心肌重塑的机制研究［D］.济南：山东大学，2011. ［17］COYLE A J,LLOYD C,TIAN J，et al.Crucial role of the interleukin-1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses［J］.J Exp Med,1999,190（7）：895-902. ［18］YIN H，LI X Y，JIN X B，et al.IL-33 prolongs murine cardiac allograft survival through induction of TH2-type immune deviation［J］.Transplantation,2010,89（10）：1189-1197. ［19］SANADA S,HAKUNO D,HIGGINS L J,et al.IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system［J］.J Clin Invest,2007,117（6）:1538-1549. ［20］SEKI K,SANADA S,KUDINOVA A Y,et al.Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling［J］.Circ Heart Fail,2009,2（6）:684-691. ［21］REHMAN S U,MUELLER T,JANUZZI J L.Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure［J］.J Am Coll of Cardiol,2008,52（18）:1458-1465. ［22］PASCUAL-FIGAL D A,MANZANO-FERNANDEZ S,BORONAT M,et al.Soluble ST2,high sensitivity troponin T and N-terminal pro-B-type natriuretic peptide:complementary role for risk stratification in acutely decompensated heart failure［J］.Eur J Heart Fail,2011,13（7）:718-725. ［23］MANZANO-FERNANDEZ S,JANUZZI J L,PASTOR-PEREZ F J,et al.Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure［J］.Cardiology,2012,122（3）:158-166. ［24］SHAH R V,CHEN-TOURNOUX A,PICARD M H,et al.Serum levels of the interleukin-1 receptor family member ST2,cardiac structure and function,and long-term mortality in patients with acute dyspnea［J］.Circ Heart Fail,2009,2（4）:311-319. ［25］PASCUAL-FIGAL D A,ORDONEZ-LLANOS J,TORNEL P L,et al.Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction［J］.J Am Coll Cardiol,2009,54（23）:2174-2179. ［26］GAGGIN H K,SZYMONIFKA J,BHARDWAJ A,et al.Head-to-head comparison of serial soluble ST2,growth differentiation factor-15,and highly-sensitive troponin T measurements in patients with chronic heart failure［J］.JACC Heart Fail,2014,2（1）:65-72. ［27］GRUSON D,LEPOUTRE T,ROUSSEAU M F,et al.Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction［J］.Int J Cardiol,2014,172（1）:e250-252. ［28］BAYES-GENIS A,DE ANTONIO M,VILA J,et al.Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification:ST2 versus galectin-3［J］.J Am Col Cardiol,2014,63（2）:158-166. ［29］ZILINSKI J L,SHAH R V,GAGGIN H K,et al.Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy［J］.Crit Care,2012,16（4）:R135. ［30］GAGGIN H K,MOTIWALA S,BHARDWAJ A,et al.Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure［J］.Circ Heart Fail,2013,6（6）:1206-1213. ［31］ANAND I S,RECTOR T S,KUSKOWSKI M,et al.Prognostic value of soluble ST2 in the valsartan heart failure trial［J］.Circ Heart Fail,2014,7（3）:418-426. ［32］LAX A,SANCHEZ-MAS J,ASENSIO-LOPEZ M C,et al.Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction［J］.JACC Heart Fail,2015,3（1）:50-58. ［33］TANG W H,WU Y,GRODIN J L，et al.Prognostic value of baseline and changes in circulating soluble ST2 levels and the effects of nesiritide in acute decompensated heart failure［J］.JACC Heart Fail,2016,4（1）:68-77. ［34］WANG T J,WOLLERT K C,LARSON M G,et al.Prognostic utility of novel biomarkers of cardiovascular stress:the Framingham Heart Study［J］.Circulation,2012,126（13）:1596-1604. ［35］COGLIANESE E E,LARSON M G,VASAN R S,et al.Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study［J］.Clin Chem,2012，58（12）：1673-1681. ［36］MUELLER T,ZIMMERMANN M,DIEPLINGER B,et al.Comparison of plasma concentrations of soluble ST2 measured by three different commercially available assays:the MBL ST2 assay,the Presage ST2 assay,and the R&D ST2 assay［J］.Clin Chim Acta,2012,13（19/20）:1493-1494. ［37］BAYES-GENIS A,ZHANG Y,KY B.ST2 and patient prognosis in chronic heart failure［J］.Am J Cardiol,2015,115（7 Suppl）:64B-69. ［38］MAISEL A S,RICHARDS A M,PASCUAL-FIGAL D,et al.Serial ST2 testing in hospitalized patients with acute heart failure［J］.Am J Cardiol,2015,115（7 Suppl）:32B-37. ［39］PIPER S E,SHERWOOD R A,AMIN-YOUSSEF G F,et al.Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure［J］.Int J Cardiol,2015,178:284-291. ［40］KIM M S,JEONG T D,HAN S B,et al.Role of soluble ST2 as a prognostic marker in patients with acute heart failure and renal insufficiency［J］.J Korean Med Sci,2015,30（5）:569-575. ［41］MEBBAZA A,DI SOMMA S,MAISEL A E,et al.ST2 and multimarker testing in acute decompensated heart failure［J］.Am J Cardiol,2015,115（7 Suppl）:38B-43. ［42］FRI ES F,LOUREN O P,LASZCZYNSKA O,et al.Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction［J］.Clin Res Cardiol,2015,104（6）:491-499. ［43］VAN KIMMENADE R R,JANUZZI J L.Emerging biomarkers in heart failure［J］.Clin Chem,2012,58（1）:127-138.

[1]	WANG Lina, LEI Jingshu, LI Kuibao, WANG Ruiying, LI Xinmiao, WANG Fangfang, GUO Xiaorong, NIU Ruihao, ZHAO Wei, ZHOU Fangfang, ZHAO Jingjing, LEE CHONGYOU. Review on Inflammatory Response in Patients with Acute Myocardial Infarction [J]. Chinese General Practice, 2026, 29(06): 790-801.
[2]	LEI Chunxin, ZHANG Xiya, ZHANG Yan, CHEN Jiaqi, LIU Zihan, LUO Jing, TAO Qingwen. Clinical Characteristics and Influencing Factors of Primary Sjögren's Disease with Dryness and Blood-stasis Syndrome [J]. Chinese General Practice, 2026, 29(06): 718-725.
[3]	WANG Xue, YANG Chengming, WANG Ziyun, ZHOU Zhong. Analysis on Prognosis and Influencing Factors in Patients with Post-tuberculosis Bronchiectasis [J]. Chinese General Practice, 2026, 29(05): 606-611.
[4]	FU Jiyi, ZHENG Boyue, WU Jiafei, WANG Jun, LI Hui. Efficacy and Safety of a Combined Regimen of Histone Deacetylase Inhibitors Venetoclax and Azacitidine in Adult T-cell Acute Lymphoblastic Leukemia [J]. Chinese General Practice, 2026, 29(04): 483-489.
[5]	WANG Yiheng, XU Xiaoming, XIA Yunlong, XIA Linying, HAN Xue, GUO Yongzhen, LIU Quanchi, YAN Wenjun. Progress in Pharmacotherapy of Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2026, 29(03): 403-408.
[6]	JIANG Xiaorui, YAN Yuyao, WEI Jingjing, QIAO Lijie, PENG Guangcao, ZHU Mingjun. Systematic Review of Risk Prediction Models for Concurrent Heart Failure with Coronary Heart Disease [J]. Chinese General Practice, 2026, 29(03): 393-402.
[7]	ZHOU Qianmei, MIAO Kali, ZHONG Yongming, ZHANG Fuman, ZHANG Zhe, LI Chengyi. Gas6 Expression in Breast Cancer and Correlation with Clinical Pathological Features and Prognosis [J]. Chinese General Practice, 2025, 28(35): 4449-4456.
[8]	LIU Yongcheng, LIU Siyu, LIANG Xiaoyu, HAO Xiaopeng, WEI Yue, DONG Guoju. Analysis of Echocardiographic Outcome Measures in Randomized Controlled Trials in Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2025, 28(33): 4140-4147.
[9]	MA Shuangshuang, XING Yanjiang, ZHANG Jiawei, WANG Jing. Research Progress on Cardiac Energy Metabolic Changes in Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2025, 28(30): 3831-3840.
[10]	NONG Jingtang, YANG Chengmin, MO Shenglong, LU Zhicheng, TANG Lina, JIAN Chongdong, SHANG Jingwei. Research Progress on Prognostic Biomarkers after Cerebral Infarction: Mechanisms and Clinical Applications [J]. Chinese General Practice, 2025, 28(29): 3711-3720.
[11]	LI Yibing, JIA Hongbo, FAN Xiaonong, ZHAO Wenjun, LIU Wei, GE Wenyi, LI Songjiao, LEI Kangchen, ZHANG Menglong, ZHANG Weiwei, CHEN Yang, LI Li. Comprehensive Evaluation of Prognostic Factors Affecting Dysphagia after Stroke: an Umbrella Review [J]. Chinese General Practice, 2025, 28(29): 3631-3637.
[12]	DENG Jie, QI Qi, WU Xinyu, HAN Quanle, LI Lei, JIANG Yue, YU Jing, WU Ruojie, WU Shouling, LI Kangbo. Cohort Study on the Association between the Atherogenic Index of Plasma and the Risk of Incident Heart Failure in a Physical Examination Population [J]. Chinese General Practice, 2025, 28(29): 3645-3652.
[13]	LIU Zhenyu, WEI Yunpeng, WANG Jiangmin, XING Yan. Causal Association Study between Sleep Duration and Heart Failure [J]. Chinese General Practice, 2025, 28(27): 3441-3446.
[14]	XU Yanpeng, HUANG Pe, ZHANG Pingping, LUO Yan, SHI Xiaoqi, WU Liusong, CHEN Yan, HE Zhixu. Expression of β-Adrenergic Receptors in Acute T-cell Lymphoblastic Leukemia and Its Clinical Significance [J]. Chinese General Practice, 2025, 28(27): 3391-3398.
[15]	LIU Wenjie, SUN Huang, LUO Wei, CHEN Xuan, PENG Yunzhu, LI Ruijie, MA Mier. Wearable Acoustic-electrocardiographic Remote Monitoring Device for Heart Failure [J]. Chinese General Practice, 2025, 28(25): 3104-3109.